RARE DISEASE
Dyskeratosis congenita
Dyskeratosis congenita
Dyskeratosis congenita
Synonyms: DC, DKC, Zinsser-Engman-Cole syndrome
Synonyms: DC, DKC, Zinsser-Engman-Cole syndrome
Synonyms: DC, DKC, Zinsser-Engman-Cole syndrome
Drug discovery
2
drugs
With orphan designations
Overview
Dyskeratosis congenita (DC) is a rare, multisystem telomere biology disorder characterized by the classic triad of nail dystrophy, lacy skin pigmentation, and oral leukoplakia. It predisposes to bone marrow failure (BMF), pulmonary fibrosis, and cancer (especially squamous cell carcinoma and hematologic malignancies). Caused by mutations in telomere-maintenance genes (TERT, TERC, DKC1, etc.), it follows X-linked, autosomal dominant, or recessive inheritance. Diagnosis combines clinical features, genetic testing, and telomere length analysis [1][2][4][13].
Burden
Leading causes of death: BMF (60–70%), pulmonary fibrosis (10–15%), and cancer (10%) [14][13].
High morbidity: Esophageal strictures (50% by adulthood), liver disease, and developmental delays in severe variants [7][19].
Progressive course with median survival often curtailed by complications [7][13].
Therapies
BMF management: Androgens (oxymetholone), hematopoietic growth factors (G-CSF), and hematopoietic stem cell transplant (HSCT) [12][13].
Emerging therapies: Preclinical Wnt pathway activation (e.g., lithium) reverses intestinal phenotypes [3][8].
Supportive care: Cancer surveillance, pulmonary/liver monitoring, and multidisciplinary follow-up [6][12].
Categories: rare developmental anomalies during embryogenesis, rare genetic diseases, rare hematological diseases, rare immunological diseases, rare neoplastic diseases, rare neurological diseases, rare ophthalmic disorders, rare skin diseases, rare transplant-related disorders
Research Papers
376 drug discovery papers about Dyskeratosis congenita, with 7 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
376 drug discovery papers about Dyskeratosis congenita, with 7 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-07 | The potential of gene therapy to rescue telomeric and extratelomeric defects in X-linked dyskeratosis congenita.
Dyskeratosis congenita (DC) is a rare inherited disorder characterized by bone marrow failure, pulmonary fibrosis, and cancer predisposition. X-linked DC (X-DC) is caused by mutations in the DKC1 gene, which encodes dyskerin, a multifunctional protein that is essential for telomere maintenance and multiple RNA-associated processes. Here, we first generated human X-DC HSPC models by introducing DKC1 frameshift mutations or the hypomorphic c.196 A>G mutation, into cord blood CD34+ cells from healthy male donors. These X-DC-like HSPCs recapitulated key hematopoietic features of the disease, including impaired proliferation, defective telomere maintenance and altered rRNA maturation. To correct these defects, lentiviral vectors were constructed carrying DKC1 under the PGK promoter or a weaker promoter driven by TERC regulatory sequences. While PGK-driven expression of dyskerin only restored the proliferation of X-DC-like HSPCs, pTERC-mediated expression of dyskerin also corrected the telomere maintenance and rRNA maturation defects characteristic of X-DC cells, without altering the functional properties of healthy HSPCs. These findings indicate that TERC promoter-driven dyskerin expression can functionally rescue key telomeric and extratelomeric defects in HSPCs carrying frameshift or hypomorphic DKC1 mutations, supporting further preclinical development of this strategy and providing a rationale for its evaluation as a therapeutic approach for X-linked dyskeratosis congenita.
2026-07-17 | Telomere and Aging Why Your Chromosome Has Shoelace TipsTelomeres—the repetitive nucleoprotein caps at the ends of linear chromosomes—function as protective "aglets" that prevent genomic instability and progressive DNA loss. This review synthesizes four decades of telomere research, from the discovery of the end‑replication problem to the latest insights into shelterin dynamics, telomerase regulation, and the non‑linear shortening of telomeres across the human lifespan. We critically examine the mechanistic links between telomere attrition, cellular senescence, oxidative stress, and mitochondrial dysfunction, and evaluate the evidence that positions telomere length as both a biomarker and a potential driver of biological aging. The clinical relevance of telomere biology is illustrated through disorders such as Dyskeratosis Congenita and the dual role of telomerase in cancer. Finally, we assess emerging interventions—from lifestyle modification to telomerase activators and gene‑editing approaches—and highlight key methodological pitfalls in telomere length measurement. By integrating structural, molecular, epidemiological, and clinical perspectives, this review provides a balanced, evidence‑based framework for understanding telomeres as central players in the aging process.
Telomeres—the repetitive nucleoprotein caps at the ends of linear chromosomes—function as protective "aglets" that prevent genomic instability and progressive DNA loss. This review synthesizes four decades of telomere research, from the discovery of the end‑replication problem to the latest insights into shelterin dynamics, telomerase regulation, and the non‑linear shortening of telomeres across the human lifespan. We critically examine the mechanistic links between telomere attrition, cellular senescence, oxidative stress, and mitochondrial dysfunction, and evaluate the evidence that positions telomere length as both a biomarker and a potential driver of biological aging. The clinical relevance of telomere biology is illustrated through disorders such as Dyskeratosis Congenita and the dual role of telomerase in cancer. Finally, we assess emerging interventions—from lifestyle modification to telomerase activators and gene‑editing approaches—and highlight key methodological pitfalls in telomere length measurement. By integrating structural, molecular, epidemiological, and clinical perspectives, this review provides a balanced, evidence‑based framework for understanding telomeres as central players in the aging process.
2026-06-02 | The R2T(P) complex orchestrates the SHQ1 driven early steps of box H/ACA snoRNP maturation
Abstract The chaperones RuvBL1 and RuvBL2 are members of the AAA+ ATPase family and participate in diverse cellular processes, including DNA repair, transcriptional regulation, and assembly of macromolecular complexes such as snoRNPs. The biogenesis of box H/ACA snoRNPs additionally requires the assembly factor SHQ1. These protein-RNA complexes are essential for ribosome biogenesis and telomerase stability and are linked to diseases such as dyskeratosis congenita and cancer. Despite detailed knowledge of mature complexes, their assembly mechanisms and how they can be modulated remain unclear. We characterize a trimeric interaction between SHQ1 and RuvBL1:RuvBL2, providing insight into early maturation of the protein-only precursor of box H/ACA snoRNPs. SHQ1 binds the flexible domain II of RuvBL1:RuvBL2, corresponding to the dodecamerization interface, suggesting disruption of this interface and promotion of hexamer formation. We further purified a complex containing RuvBL1:RuvBL2, SHQ1, and DKC1, the catalytic component of H/ACA snoRNPs and a client of SHQ1. This demonstrates that SHQ1 and DKC1 can simultaneously associate with RuvBL1:RuvBL2, potentially facilitating DKC1 release and subsequent snoRNA binding. Additionally, we identified a direct interaction between SHQ1 and RPAP3, a co-chaperone of RuvBL1:RuvBL2 (within the R2TP). Hence, RPAP3 may be responsible for recruiting SHQ1:DKC1 to hexameric RuvBL1:RuvBL2 and/or assist in the AAA+ mediated dissociation of the dimer. Since SHQ1 shares a domain with PIH1D1, an integral member of the R2TP complex, our findings suggest that early H/ACA snoRNP maturation may involve the R2T instead of the previously proposed R2TP complex.
2026-05-01 | C29-13 Somatic Variants Rescue Bone Marrow Failure, But Not Lung Disease in Patients With Germline Variants in TINF2
Abstract Introduction Telomeres are essential for genome maintenance. Rare variants disrupting telomere maintenance genes cause a spectrum of short telomere syndromes, with idiopathic pulmonary fibrosis (IPF) as the most common phenotype. Variants in the shelterin component TIN2 typically cause severe pediatric dyskeratosis congenita (DC) and bone marrow failure. However, a subset of patients with germline TINF2 variants presents with less severe, adult-onset disease, including IPF, suggesting the presence of modifying factors. Methods We identified three patients with pathogenic germline TINF2 hotspot variants evaluated at the University of Pittsburgh Medical Center for lung transplantation. Two had a family history of DC; one had a sporadic presentation. Clinical genetic testing and deep exome sequencing was used to identify somatic variants. We validated the function of somatic variants in vitro using CRISPR/Cas9-mediated genome editing in multiple cell lines and in patient-derived induced pluripotent stem cells (iPSCs). Results All three patients had somatic variants in the DNA-binding domain of POT1 where tumor-specific variants have been previously reported. Edited cells showed no signs of DNA damage, genomic instability, or altered growth kinetics. Telomeres progressively lengthened in all edited lines. iPSCs reprogrammed from patient PBMCs, which harbored both the germline TINF2 and somatic POT1 variants, also demonstrated gradual telomere lengthening, verifying the POT1 variants are functional and sufficient for telomere elongation, even in the context of the pathogenic TINF2 variant. Conclusions Somatic POT1 variants appear to rescue hematopoietic function and cause telomere lengthening in vitro. POT1 editing is efficient and does not appear to influence genome stability. We propose that genetically modifying POT1 may be an effective therapy to rescue the bone marrow of patients with short telomeres. This abstract is funded by: NA
2026-04-25 | Mathematical modelling of premature haematopoietic ageing in dyskeratosis congenita.
Idiopathic dyskeratosis congenita (DC) is a disorder characterized by mucocutaneous alterations, bone-marrow failure, immune deficiency, liver cirrhosis, and other morbidities, due to alterations in telomere maintenance, which, in most cases, lead to short telomeres and poor tissue regeneration and function. The main cause of mortality is bone-marrow failure. A non-local diffusion-advection model with zero-flux boundary conditions is used to simulate the generational and temporal evolution of a hematopoietic stem cell (HSC) population in order to investigate the progression of DC. Blood-cell production from progenitor cells that had exited the HSC compartment was quantified. The influence of variations in initial proliferation potential ([Formula: see text]) and telomerase activity (s) on the onset of pancytopenia was examined. Age-and weight-dependent blood cell demands are modeled for both sexes, establishing a physiological baseline against which DC-related deficiencies are compared. Simulations revealed that lower [Formula: see text] values and reduced telomerase activity accelerate stem cell exhaustion, resulting in early pancytopenia, sometimes before age of 2 years. In contrast, patients with moderately higher [Formula: see text] values developed pancytopenia later in life, with onset delayed until the third or fourth decade. Treatment simulations demonstrated that a two-year course of danazol, a synthetic androgen, can slow telomere attrition. These findings suggest that pharmacological intervention may delay hematopoietic failure and possibly improve the production of oocytes with better-preserved telomeres in female DC patients. Our model provides a valuable framework for assessing (or understanding, or both) disease progression and evaluating therapeutic strategies in telomeropathy-associated bone marrow failure.
2026-08-07 | The potential of gene therapy to rescue telomeric and extratelomeric defects in X-linked dyskeratosis congenita.
Dyskeratosis congenita (DC) is a rare inherited disorder characterized by bone marrow failure, pulmonary fibrosis, and cancer predisposition. X-linked DC (X-DC) is caused by mutations in the DKC1 gene, which encodes dyskerin, a multifunctional protein that is essential for telomere maintenance and multiple RNA-associated processes. Here, we first generated human X-DC HSPC models by introducing DKC1 frameshift mutations or the hypomorphic c.196 A>G mutation, into cord blood CD34+ cells from healthy male donors. These X-DC-like HSPCs recapitulated key hematopoietic features of the disease, including impaired proliferation, defective telomere maintenance and altered rRNA maturation. To correct these defects, lentiviral vectors were constructed carrying DKC1 under the PGK promoter or a weaker promoter driven by TERC regulatory sequences. While PGK-driven expression of dyskerin only restored the proliferation of X-DC-like HSPCs, pTERC-mediated expression of dyskerin also corrected the telomere maintenance and rRNA maturation defects characteristic of X-DC cells, without altering the functional properties of healthy HSPCs. These findings indicate that TERC promoter-driven dyskerin expression can functionally rescue key telomeric and extratelomeric defects in HSPCs carrying frameshift or hypomorphic DKC1 mutations, supporting further preclinical development of this strategy and providing a rationale for its evaluation as a therapeutic approach for X-linked dyskeratosis congenita.
2026-07-17 | Telomere and Aging Why Your Chromosome Has Shoelace TipsTelomeres—the repetitive nucleoprotein caps at the ends of linear chromosomes—function as protective "aglets" that prevent genomic instability and progressive DNA loss. This review synthesizes four decades of telomere research, from the discovery of the end‑replication problem to the latest insights into shelterin dynamics, telomerase regulation, and the non‑linear shortening of telomeres across the human lifespan. We critically examine the mechanistic links between telomere attrition, cellular senescence, oxidative stress, and mitochondrial dysfunction, and evaluate the evidence that positions telomere length as both a biomarker and a potential driver of biological aging. The clinical relevance of telomere biology is illustrated through disorders such as Dyskeratosis Congenita and the dual role of telomerase in cancer. Finally, we assess emerging interventions—from lifestyle modification to telomerase activators and gene‑editing approaches—and highlight key methodological pitfalls in telomere length measurement. By integrating structural, molecular, epidemiological, and clinical perspectives, this review provides a balanced, evidence‑based framework for understanding telomeres as central players in the aging process.
Telomeres—the repetitive nucleoprotein caps at the ends of linear chromosomes—function as protective "aglets" that prevent genomic instability and progressive DNA loss. This review synthesizes four decades of telomere research, from the discovery of the end‑replication problem to the latest insights into shelterin dynamics, telomerase regulation, and the non‑linear shortening of telomeres across the human lifespan. We critically examine the mechanistic links between telomere attrition, cellular senescence, oxidative stress, and mitochondrial dysfunction, and evaluate the evidence that positions telomere length as both a biomarker and a potential driver of biological aging. The clinical relevance of telomere biology is illustrated through disorders such as Dyskeratosis Congenita and the dual role of telomerase in cancer. Finally, we assess emerging interventions—from lifestyle modification to telomerase activators and gene‑editing approaches—and highlight key methodological pitfalls in telomere length measurement. By integrating structural, molecular, epidemiological, and clinical perspectives, this review provides a balanced, evidence‑based framework for understanding telomeres as central players in the aging process.
2026-06-02 | The R2T(P) complex orchestrates the SHQ1 driven early steps of box H/ACA snoRNP maturation
Abstract The chaperones RuvBL1 and RuvBL2 are members of the AAA+ ATPase family and participate in diverse cellular processes, including DNA repair, transcriptional regulation, and assembly of macromolecular complexes such as snoRNPs. The biogenesis of box H/ACA snoRNPs additionally requires the assembly factor SHQ1. These protein-RNA complexes are essential for ribosome biogenesis and telomerase stability and are linked to diseases such as dyskeratosis congenita and cancer. Despite detailed knowledge of mature complexes, their assembly mechanisms and how they can be modulated remain unclear. We characterize a trimeric interaction between SHQ1 and RuvBL1:RuvBL2, providing insight into early maturation of the protein-only precursor of box H/ACA snoRNPs. SHQ1 binds the flexible domain II of RuvBL1:RuvBL2, corresponding to the dodecamerization interface, suggesting disruption of this interface and promotion of hexamer formation. We further purified a complex containing RuvBL1:RuvBL2, SHQ1, and DKC1, the catalytic component of H/ACA snoRNPs and a client of SHQ1. This demonstrates that SHQ1 and DKC1 can simultaneously associate with RuvBL1:RuvBL2, potentially facilitating DKC1 release and subsequent snoRNA binding. Additionally, we identified a direct interaction between SHQ1 and RPAP3, a co-chaperone of RuvBL1:RuvBL2 (within the R2TP). Hence, RPAP3 may be responsible for recruiting SHQ1:DKC1 to hexameric RuvBL1:RuvBL2 and/or assist in the AAA+ mediated dissociation of the dimer. Since SHQ1 shares a domain with PIH1D1, an integral member of the R2TP complex, our findings suggest that early H/ACA snoRNP maturation may involve the R2T instead of the previously proposed R2TP complex.
2026-05-01 | C29-13 Somatic Variants Rescue Bone Marrow Failure, But Not Lung Disease in Patients With Germline Variants in TINF2
Abstract Introduction Telomeres are essential for genome maintenance. Rare variants disrupting telomere maintenance genes cause a spectrum of short telomere syndromes, with idiopathic pulmonary fibrosis (IPF) as the most common phenotype. Variants in the shelterin component TIN2 typically cause severe pediatric dyskeratosis congenita (DC) and bone marrow failure. However, a subset of patients with germline TINF2 variants presents with less severe, adult-onset disease, including IPF, suggesting the presence of modifying factors. Methods We identified three patients with pathogenic germline TINF2 hotspot variants evaluated at the University of Pittsburgh Medical Center for lung transplantation. Two had a family history of DC; one had a sporadic presentation. Clinical genetic testing and deep exome sequencing was used to identify somatic variants. We validated the function of somatic variants in vitro using CRISPR/Cas9-mediated genome editing in multiple cell lines and in patient-derived induced pluripotent stem cells (iPSCs). Results All three patients had somatic variants in the DNA-binding domain of POT1 where tumor-specific variants have been previously reported. Edited cells showed no signs of DNA damage, genomic instability, or altered growth kinetics. Telomeres progressively lengthened in all edited lines. iPSCs reprogrammed from patient PBMCs, which harbored both the germline TINF2 and somatic POT1 variants, also demonstrated gradual telomere lengthening, verifying the POT1 variants are functional and sufficient for telomere elongation, even in the context of the pathogenic TINF2 variant. Conclusions Somatic POT1 variants appear to rescue hematopoietic function and cause telomere lengthening in vitro. POT1 editing is efficient and does not appear to influence genome stability. We propose that genetically modifying POT1 may be an effective therapy to rescue the bone marrow of patients with short telomeres. This abstract is funded by: NA
2026-04-25 | Mathematical modelling of premature haematopoietic ageing in dyskeratosis congenita.
Idiopathic dyskeratosis congenita (DC) is a disorder characterized by mucocutaneous alterations, bone-marrow failure, immune deficiency, liver cirrhosis, and other morbidities, due to alterations in telomere maintenance, which, in most cases, lead to short telomeres and poor tissue regeneration and function. The main cause of mortality is bone-marrow failure. A non-local diffusion-advection model with zero-flux boundary conditions is used to simulate the generational and temporal evolution of a hematopoietic stem cell (HSC) population in order to investigate the progression of DC. Blood-cell production from progenitor cells that had exited the HSC compartment was quantified. The influence of variations in initial proliferation potential ([Formula: see text]) and telomerase activity (s) on the onset of pancytopenia was examined. Age-and weight-dependent blood cell demands are modeled for both sexes, establishing a physiological baseline against which DC-related deficiencies are compared. Simulations revealed that lower [Formula: see text] values and reduced telomerase activity accelerate stem cell exhaustion, resulting in early pancytopenia, sometimes before age of 2 years. In contrast, patients with moderately higher [Formula: see text] values developed pancytopenia later in life, with onset delayed until the third or fourth decade. Treatment simulations demonstrated that a two-year course of danazol, a synthetic androgen, can slow telomere attrition. These findings suggest that pharmacological intervention may delay hematopoietic failure and possibly improve the production of oocytes with better-preserved telomeres in female DC patients. Our model provides a valuable framework for assessing (or understanding, or both) disease progression and evaluating therapeutic strategies in telomeropathy-associated bone marrow failure.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
2 orphan drug designations for Dyskeratosis congenita.
2 orphan drug designations for Dyskeratosis congenita.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
autologous CD34+ cells contacted ex vivo with EXG-001 Sendai virus vector | gene therapies | FDA | 2025-02-20 | — | Elixirgen Therapeutics, Inc. |
Recombinant human dyskerin | proteins | EMA | 2012-11-08 | — | Advanced Medical Projects |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.